2171 Stock Overview An investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies and solid tumors in China and the United States. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
CARsgen Therapeutics Holdings Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for CARsgen Therapeutics Holdings Historical stock prices Current Share Price HK$10.08 52 Week High HK$11.78 52 Week Low HK$2.48 Beta 0.24 1 Month Change 9.45% 3 Month Change 110.44% 1 Year Change 147.06% 3 Year Change -40.71% 5 Year Change n/a Change since IPO -77.35%
Recent News & Updates
CARsgen's Allogeneic CD38 CAR-T Therapy Administers First Dose in an Investigator-Initiated Trial Jan 21
CARsgen's Allogeneic CD19/CD20 CAR-T Therapy Administers First Dose in an Investigator-Initiated Trial Jan 14
CARsgen Announces the Initiation of an Investigator-Initiated Trial for an Allogeneic CD19/CD20 CAR-T Therapy Jan 01
CARsgen Therapeutics Holdings Limited Announces Positive Results from the Pivotal Phase II Clinical Trial CT041-ST-01 (NCT04581473) Dec 30
New major risk - Share price stability Nov 12
CARsgen Therapeutics Holdings Limited Announces That the U.S. Food and Drug Administration (FDA) Loses the Clinical Holds on Clinical Trials of Zevor-Ccel Nov 01 See more updates
CARsgen's Allogeneic CD38 CAR-T Therapy Administers First Dose in an Investigator-Initiated Trial Jan 21
CARsgen's Allogeneic CD19/CD20 CAR-T Therapy Administers First Dose in an Investigator-Initiated Trial Jan 14
CARsgen Announces the Initiation of an Investigator-Initiated Trial for an Allogeneic CD19/CD20 CAR-T Therapy Jan 01
CARsgen Therapeutics Holdings Limited Announces Positive Results from the Pivotal Phase II Clinical Trial CT041-ST-01 (NCT04581473) Dec 30
New major risk - Share price stability Nov 12
CARsgen Therapeutics Holdings Limited Announces That the U.S. Food and Drug Administration (FDA) Loses the Clinical Holds on Clinical Trials of Zevor-Ccel Nov 01
Carsgen Therapeutics Holdings Limited Submits Application to Request Lifting Clinical Holds to FDA Oct 09
CARsgen Therapeutics Holdings Limited Announces Completion of Enrollment of Confirmatory Phase II Clinical Trial of Satricabtagene Autoleucel in China Aug 19
CARsgen Therapeutics Holdings Limited to Report First Half, 2024 Results on Aug 28, 2024 Aug 15
New minor risk - Share price stability Jun 25
Non-Executive Director recently bought HK$903k worth of stock Jun 20
Carsgen Therapeutics Holdings Limited Provides Updated Research Results on SATRI-CEL in Nature Medicine And At the 2024 Asco Annual Meeting Jun 05
Non-Executive Director recently bought HK$937k worth of stock May 29
CARsgen Therapeutics Holdings Limited Submits Responses to FDA Observations Apr 30
CARsgen Therapeutics Holdings Limited, Annual General Meeting, May 21, 2024 Mar 27
CARsgen Therapeutics Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024 Mar 14
New major risk - Share price stability Feb 22
Carsgen Therapeutics Holdings Limited Announces Updated Clinical Research Results on CT041 at 2024 ASCO GI Meeting Jan 20
CARsgen Therapeutics Holdings Limited Announces CT011 Achieve Investigational New Drug (IND) Clearance from the National Medical Products Administration Jan 16
CARsgen Therapeutics Holdings Limited Announces Updated Research Results on Zevor-cel At 2023 American Society of Hematology Annual Meeting Dec 12
CARsgen Therapeutics Holdings Limited Receives Investigational New Drug Clearance from the FDA for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma Dec 05
CARsgen Therapeutics Holdings Limited Announces Abstract of Zevorcabtagene Autoleucel Accepted for Poster at 2023 Ash Annual Meeting Oct 21
CARsgen Therapeutics Holdings Limited Car-Gpc3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Two Patients Achieved over 7 Years of Disease-Free Survival Oct 13
CARsgen Therapeutics Holdings Limited to Report First Half, 2023 Results on Aug 22, 2023 Aug 11
CARsgen Therapeutics Holdings Limited Appoints Xiangke Zhao as Independent Non-Executive Director and the Chairperson of the Audit Committee Jul 06
Carsgen Therapeutics Holdings Limited Announces Resignation of Tak Young So as an Independent Non-Executive Director and Chairman of the Audit Committee Jun 16
CARsgen Therapeutics Holdings Limited Initiates Patient Enrollment for Phase 2 Clinical Trial for CT041 May 19
CARsgen Therapeutics Holdings Limited's CLDN18.2 Mab Ab011 Achieves IND Clearance from the NMPA for the First-Line Combination Treatment of Gastric Cancer May 06
CARsgen Therapeutics Holdings Limited Presents Results on Anti-Claudin18.2-mAb AB011 at ASCO GI Jan 21
CARsgen Therapeutics Holdings Limited Announces Resignation of Chunhai FAN as Independent Non-Executive Director Jan 12
Insider recently sold HK$14m worth of stock Jan 10
CARsgen Presents Data from China Pivotal Phase II Trial of BCMA CAR T Zevor-cel (CT053) at 2022 ASH Annual Meeting Dec 13
Less than half of directors are independent Nov 16
CARsgen Therapeutics Holdings Limited Appoints Sylvie Peltier as Senior Vice President of Global Regulatory Affairs Nov 01 CARsgen Therapeutics Holdings Limited Announces NDA Acceptance of BCMA CAR T Zevor-cel (CT053) by China NMPA
Carsgen Therapeutics Holdings Limited Releases First Clinical Batch from the RTP GMP Manufacturing Facility in North Carolina Sep 02
CARsgen Therapeutics Holdings Limited Announces Case Report of Long Term Complete Response in Hepatocellular Carcinoma to It's GPC3 CAR T Cells (CT011) Published in Frontiers in Immunology Aug 19
CARsgen Therapeutics Holdings Limited to Report First Half, 2022 Results on Aug 23, 2022 Aug 12
CARsgen Therapeutics Holdings Limited Announces Appointment of Dr. Hua JIANG as Executive Director Aug 02
CARsgen Therapeutics Holdings Limited Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2022 Jul 23
Insider recently sold HK$8.8m worth of stock Jul 09
Insider recently sold HK$14m worth of stock Jun 30
Insider recently sold HK$1.9m worth of stock Jun 22
Insider recently sold HK$10m worth of stock Jun 14
Carsgen TheCARsgen Therapeutics Holdings Limited Presents Updated Data for CT041 Claudin18.2 CAR T-cells in Solid Tumors at ASCO 2022 Jun 07
CARsgen Therapeutics Holdings Limited Announces Resignation of Zhao Yachao as Non-Executive Director May 28
Insider recently sold HK$3.0m worth of stock May 26 CARsgen Therapeutics Holdings Limited Announces Results of the Investigator-Initiated Trial of CT041 Were Reported in the Nature Medicine
Less than half of directors are independent Apr 27
CARsgen Therapeutics Holdings Limited, Annual General Meeting, May 25, 2022 Apr 22
Carsgen Therapeutics Holdings Limited Appoints Dr. Raffaele Baffa as Chief Medical Officer Apr 08
CARsgen Therapeutics Holdings Limited Announces Approval from Center for Drug Evaluation of National Medical Products Administration of China for the Initiation of the CT041 Confirmatory Phase II Clinical Trial Mar 05
CARsgen Therapeutics Holdings Limited Announces United States Food and Drug Administration Grants Regenerative Medicine Advanced Therapy Designation to CT041 Jan 12
CARsgen Therapeutics Holdings Limited Announces Clinical Trial Application for Ct041 Authorised by Health Canada Nov 24 Shareholder Returns 2171 HK Biotechs HK Market 7D -3.1% 0.5% 1.8% 1Y 147.1% 10.8% 24.2%
See full shareholder returns
Return vs Market: 2171 exceeded the Hong Kong Market which returned 24.4% over the past year.
Price Volatility Is 2171's price volatile compared to industry and market? 2171 volatility 2171 Average Weekly Movement 20.2% Biotechs Industry Average Movement 8.0% Market Average Movement 6.5% 10% most volatile stocks in HK Market 13.9% 10% least volatile stocks in HK Market 3.0%
Stable Share Price: 2171's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2171's weekly volatility has increased from 14% to 20% over the past year.
About the Company CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies and solid tumors in China and the United States. The company is developing autologous CAR-T product candidates, including CT053, which targets B-cell maturation antigen that is in pivotal Phase II/III trial for the treatment of relapsed/refractory multiple myeloma; CT041, which targets Claudin 18.2, is in Phase II/III clinical trial for gastric/gastroesophageal junction cancer and pancreatic cancer, as well as in Phase I clinical trial for gastric or pancreatic cancer; CT011, which is in Phase I clinical trial for patients with Glypican-3 positive IIIa hepatocellular carcinoma (HCC); and CT071, that is in Phase I clinical trial which targets G protein-coupled receptor class C group 5 member D for the treatment of R/R MM and relapsed/refractory primary plasma cell leukemia (R/R pPCL). It is also developing CT0180 and CT0181, which targets Glypican-3 that is in Phase I clinical trial for the treatment of hepatocellular carcinoma.
Show more CARsgen Therapeutics Holdings Limited Fundamentals Summary How do CARsgen Therapeutics Holdings's earnings and revenue compare to its market cap? 2171 fundamental statistics Market cap HK$5.53b Earnings (TTM ) -HK$746.68m Revenue (TTM ) HK$6.81m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 2171 income statement (TTM ) Revenue CN¥6.34m Cost of Revenue CN¥4.72m Gross Profit CN¥1.62m Other Expenses CN¥696.50m Earnings -CN¥694.88m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -1.27 Gross Margin 25.50% Net Profit Margin -10,960.25% Debt/Equity Ratio 8.6%
How did 2171 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/30 21:58 End of Day Share Price 2025/01/28 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources CARsgen Therapeutics Holdings Limited is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Xiao Wei Lin Everbright Securities Co. Ltd. Ziyi Chen Goldman Sachs
Show 0 more analysts 